2 min read
MANCHESTER, NH, APRIL 30, 2024 — Alumni Ventures (AV), one of the world’s most active venture capital firms, is proud to support Nanopath, a trailblazing molecular diagnostics company focused on women’s health. In 2022, AV invested in Nanopath’s $10 million Series A led by Norwest Venture Partners and the Medtech Convergence Fund, an SV Health Investors Fund. The funding has helped to catalyze further development and commercialization of the company’s biosensing platform.
by Alumni Ventures